Executive Team

 

Dr. David C. Bonner, Ph.D

Chairman & CEO

Dr. Bonner has extensive experience in executive business management globally as well as technology development, including a successful medical system commercialization. He has led seven start-up ventures and has extensive world-wide licensing experience.

Dr. Bonner earned his B.S. and M.S. degrees in Chemical Engineering from the University of Texas at Austin, and his Ph.D. degree in Chemical Engineering at the University of California, Berkeley. He was named a Distinguished Engineering Graduate of the University of Texas at Austin in 2001. He has served on several U.S. National Academy of Science and National Academy councils and committees and has been an advisor to the University of California, Berkeley, the University of Texas at Austin, Vanderbilt University, Rice University, and the University of Akron. He has served as an External Examiner in the Ph. D. Program at IMD in Lausanne, Switzerland.

David F. Bonner

Vice President of Operations

As Vice President of Operations, Mr. Bonner directs commercial operations for all of Regenevita's clinical facilities.

 

Upon leaving the United States Air Force as an officer in U.S. Space Command, Mr. Bonner joined Regenevita in 2009 and served as Representative Director of its Latin American office in Buenos Aires, Argentina. He was responsible for establishing adult-stem cell processing facilities and forming doctor/patient networks to support treatment operations in licensed territories. He is a graduate of Texas Christian University and received his MBA from the University of Wyoming.

James Rogers

Executive Vice President & CFO

Mr. Rogers was a partner in the largest independent CPA firm in Louisiana for 20 years where he specialized in audits of health care companies, not-for-profit entities and banks. He received his B.S. degree from Louisiana State University from whom he has also been awarded their Distinguished Alumni Award and earned his CPA certificate in 1973. He later formed and became an owner of a hospital where he served as CFO until he sold his interest. He was a managing member of RAGE Resources, LLC, a financial consulting firm.

Dr. Jeff Karnes, MD

Medical Advisor

Dr. Karnes applies his medical background and training to help guide the company’s adoption and ethical implementation of reparative medicine therapies for patients.  Additionally, he uses his medical knowledge and expertise to inform company decisions as well as sales strategies.  His duties include supporting sales and marketing, communicating relevant medical and scientific information to customers, and training newly partnered healthcare professionals and staff on proper procedure and technique of medical devices and products.

 

Dr. Karnes graduated with honors from Texas A&M University with a BS in Chemistry and then received his MD from Baylor College of Medicine in Houston.  While at Baylor College of Medicine, he completed a two-year research track through the Graduate School of Biomedical Sciences in Translational Biology and Molecular Medicine, investigating the role that altered arginine and nitric oxide metabolism play in diseases characterized by chronic inflammation.

 

Dr. Jonathan Lakey, Ph.D

Scientific Advisor

Dr. Lakey is currently Professor of Surgery and Biomedical Engineering at the University of California Irvine. Dr Lakey is also the Director of Surgical Research and Director of the Clinical Islet Program. Currently, he holds  a State of California Tissue Bank License and maintains the Quality Manual and SOP manual for Clinical Islet Program since 2013.

Dr. Lakey actively assists in formal reviews and audits of clinical islet transplant and research programs (Canada, US and UK) and sits on the advisory board of One Legacy Organ Procurement Organization in Southern California. Dr Lakey has served on committees within both Health Canada and American Association of Tissue banks (AATB and AABB) developing standards for cell and tissue transplantation and has had Pre IND meetings with the FDA regarding diabetes technologies on behalf of biotechnology collaborations.

Follow

©2018 by Regenevita BioCell. Proudly created with Wix.com